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Background: There is growing interest in conducting clinical and cluster randomized trials through electronic
health records. This paper reports on the methodological issues identified during the implementation of two cluster
randomized trials using the electronic health records of the Clinical Practice Research Datalink (CPRD).
Methods: Two trials were completed in primary care: one aimed to reduce inappropriate antibiotic prescribing for
acute respiratory infection; the other aimed to increase physician adherence with secondary prevention interventions
after first stroke. The paper draws on documentary records and trial datasets to report on the methodological
experience with respect to research ethics and research governance approval, general practice recruitment and
allocation, sample size calculation and power, intervention implementation, and trial analysis.
Results: We obtained research governance approvals from more than 150 primary care organizations in England,
Wales, and Scotland. There were 104 CPRD general practices recruited to the antibiotic trial and 106 to the stroke
trial, with the target number of practices being recruited within six months. Interventions were installed into
practice information systems remotely over the internet. The mean number of participants per practice was 5,588
in the antibiotic trial and 110 in the stroke trial, with the coefficient of variation of practice sizes being 0.53 and
0.56 respectively. Outcome measures showed substantial correlations between the 12 months before, and after
intervention, with coefficients ranging from 0.42 for diastolic blood pressure to 0.91 for proportion of consultations
with antibiotics prescribed, defining practice and participant eligibility for analysis requires careful consideration.
Conclusions: Cluster randomized trials may be performed efficiently in large samples from UK general practices
using the electronic health records of a primary care database. The geographical dispersal of trial sites presents a
difficulty for research governance approval and intervention implementation. Pretrial data analyses should inform
trial design and analysis plans.
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Recent developments in electronic health records (EHRs),
and their increasing accessibility for health research, have
stimulated interest in utilizing EHRs for intervention stud-
ies in clinical medicine, public health, and health services
research [1]. This approach to trial conduct offers several
potential advantages over traditional trials. Use of data
routinely collected from EHRs facilitates direct access
to large sample sizes and reduces the cost of trial im-
plementation. Trials using EHRs may also have high
external validity because of the representativeness of the
samples that may be recruited and the use of interventions
that are similar to those that may be rolled out into rou-
tine service settings. Trials using EHRs generally adopt a
pragmatic perspective [2], and are sometimes referred to
as ‘point-of-care’ trials [3].
In the UK, the main focus of interest has been in the
use of primary care EHRs collected into large data re-
sources such as the Clinical Practice Research Datalink
(CPRD) [4]. The CPRD presently includes anonymized
electronic health record data for about 7 to 8% of UK
family practices with a similar proportion of the UK
population as registered patients. General practice data
in the CPRD are subject to quality checks and, when
the data reaches set research standards, are referred to
as ‘up-to-standard’ (UTS). The high quality of CPRD
data has been extensively documented [5]. CPRD data
are presently being enriched through linkages with
other data sources including disease registry data [6,7]
and data on hospital utilisation and mortality records.
Our group has recently completed two cluster random-
ized trials using the CPRD [8,9]. These are among the first
cluster randomized trials to be performed exclusively
using electronic health records. One trial aimed to im-
prove standards of care for secondary prevention after a
stroke; this provided an exemplar of a less frequent long-
term condition of public health importance. This will be
referred to as the ‘stroke trial’. The second trial aimed to
reduce the prescribing of antibiotics to patients presenting
with respiratory tract infections in primary care. This
provided an exemplar of a common acute condition.
The trials’ designs [8,9] and substantive results [10,11]
have been reported elsewhere.
In view of the novelty of this approach to conducting
cluster trials, we present a narrative account of the ex-
perience of cluster trial performance using EHRs. This
paper aims to report on methodological issues in the
design, conduct, and analysis of these two cluster ran-
domized trials in the EHRs of CPRD. We report on issues
that were common to both trials, as well as drawing at-
tention to differences of approach where appropriate.
Issues, such as missing data, which are also relevant to
observational analyses of EHR data are not discussed
in detail.Methods
The paper draws on the authors’ experience, documentary
records of the trial, and trial datasets to report on the
main practical issues involved in designing and per-
forming a cluster randomized trial using EHRs. The
paper begins with a brief outline of the purpose and
design of the trials. It goes on to discuss ethical issues
and research governance procedures, general practice
recruitment and allocation, and sample size and power,
drawing on data from the trial datasets. The following
section discusses how the problem of intervention de-
livery was addressed. The final main section of the
paper draws attention to some issues relevant for data
analysis. The paper concludes with a brief discussion.
Statistical analyses were performed in Stata version 13
Stata Corporation, College Station, Texas. Intraclass
correlation coefficients were estimated using one way
analysis of variance. The protocol for the research was
approved by the MHRA Independent Scientific Advisory
Committee (ISAC, protocol number 08_083) and the
London-Surrey Borders NHS Research Ethics Committee
(09-H0806-81 and 10-H0806-1).
Results and discussion
Outline of trial design
The stroke trial and the antibiotic trial shared similar
objectives and design features while differing in the topic
of application and approach to data analysis. The pri-
mary purpose of the research was to develop methods to
perform cluster randomized trials using EHRs but the
substantive topic of the trials was to facilitate translation
of research evidence into practice in the areas of anti-
biotic prescribing and stroke secondary prevention. Each
trial was a two-arm cluster randomized trial with general
practice as the unit of allocation. In each trial, the active
intervention consisted of a set of educational and deci-
sion support tools that were remotely installed into the
software system of participating general practices and
activated during consultations with eligible participants.
General practices in the control trial arm continued with
usual clinical practice. The development of the interven-
tions [12] and a process evaluation of the intervention
implementation (paper submitted for publication) have
been reported elsewhere. In the antibiotic trial, eligible
participants were those consulting for acute respiratory
infections with the intervention aiming to reduce unneces-
sary antibiotic prescribing [13], following recommendations
by the UK National Institute for Health and Care Excel-
lence (NICE) [14]. In the stroke trial, participants were
eligible for the intervention if they were included in the
practice stroke register. The intervention, which was
activated during any consultation by eligible patients,
aimed to promote adherence with nationally recom-
mended standards of care for stroke [15]. There was a
Table 1 Governance approvals from UK primary care
organizations for the two trials
Invited Approved Declined
Antibiotic trial
PCTs in England 159 149 10
Health Boards in Scotland 10 10 0
Stroke trial
PCTs in England 158 141 17
Health Boards in Scotland 12 10 2
Health Boards in Wales 7 7 0
Figures are numbers of primary care organizations. PCT, primary care trust.
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evaluate participants’ baseline characteristics and trial
outcomes were drawn from data routinely recorded
into CPRD during consultations in primary care. In the
antibiotic trial, a cluster level analysis was performed
using practice-specific rates of consultation and anti-
biotic prescribing as observations, with the proportion
of consultations with antibiotics prescribed as the pri-
mary outcome. In the stroke trial, an individual level
analysis was performed on systolic blood pressure as
the primary outcome, with marginal models estimated
using generalized estimating equations.
Ethical issues and research governance
The arrangements for research ethical approval and re-
search governance for CPRD trials differ from other trials
both because general practices contributing to CPRD are
widely dispersed geographically and because general prac-
tices contribute to CPRD on an anonymized basis and it is
not possible for research teams to contact them directly.
Our experience may be relevant to the conduct of future
trials in CPRD and similar data resources.
The protocol for the research was submitted to the
Independent Scientific Advisory Committee, which is
responsible for reviewing all proposed research in CPRD.
The proposal was approved with minor revisions. The
protocol for each trial was submitted to and approved
by a local NHS Research Ethics Committee. Consent to
participation in the study was requested from a senior
partner at eligible CPRD general practices. The rationale
for consent at the cluster level was that the intervention
was implemented for the whole cluster by installing the
intervention into the general practice software system
with the practice staff being the intended recipients of
the intervention [16]. Individual patient health record
data were to be analysed to evaluate trial outcomes but
the ethical issues associated with this data collection
and analysis are covered by the overarching governance
framework of CPRD. Weijer et al. [17] argue that in tri-
als of the present type, individual patients should not be
regarded as research participants because all treatment
decisions remain the responsibility of the health profes-
sionals and are not determined by the trial allocation.
CPRD general practices participate in the database on
the basis of anonymity. For this reason, all communications
with practices were through CPRD and the trial research
team did not have any direct contact with the trial prac-
tices. However, the consent form for the study included
explicit consent for the practice to be identified to the
intervention provider in order to allow activation of the
intervention as outlined below in the event that the prac-
tice was allocated to the intervention trial arm. The con-
sent form also included an item that requested permission
for the practice to be contacted by the research team for aqualitative interview for the process evaluation of the
intervention.
In the UK, research governance approval is also re-
quired from each participating locality-based NHS or-
ganisation. This presents a difficulty for CPRD research
because general practices participating in CPRD are dis-
tributed throughout the UK, including England, Scotland,
Wales, and Northern Ireland, with each territory having
its own independent governance framework. As the loca-
tion of CPRD practices is not generally made available to
researchers, we aimed to obtain approvals from all NHS
primary care organizations in England and Scotland for
the antibiotic trial, and England, Scotland, and Wales for
the stroke trial. Northern Ireland was not included in ei-
ther trial as it is geographically more remote, but it might
be feasible to include it in future studies. In England
and Scotland, approvals were obtained through a system
known as the central system for permissions (CSP) and
NHS Research Scotland Permissions Coordinating Centre
(NRSPCC), which facilitated the approval process at each
local primary care organisation or health board (Scotland).
In Wales, approvals were obtained from each health board.
Table 1 presents data for the approvals obtained in England
and Scotland for the antibiotic trial and England, Scotland,
and Wales for the stroke trial. The majority of NHS or-
ganizations approved the trials, with 159 primary care
organizations approving the antibiotic trial and 158 ap-
proving the stroke trial. However, a number of organi-
zations declined to participate. In every case this was
because the trial interventions were perceived to con-
flict with locally developed advice for general practice
prescribing.
General practice recruitment and allocation
The recruitment process is critical to the success of most
trials. In order to deliver recruitment for these studies,
general practices participating in CPRD in areas for which
research governance approvals were obtained were sent
an invitation pack including an invitation letter, informa-
tion sheet, and consent form. Table 2 shows the rate of
Table 2 Recruitment of general practices into the two trials
Weeks from first
invitation letter
Event Cumulative number of
general practices allocated
Antibiotic trial 0 First invitation, England 0
5 34 practices allocated 34
7 Reminder, England; first invitation Scotland 34
13 37 practices allocated 71
16 Reminder, Scotland 71
19 19 practices allocated 90
23 11 practices allocated 101
27 3 practices allocated 104
Stroke trial 0 First invitation 0
5 71 practices allocated 71
14 28 practices allocated 99
21 7 practices allocated 106
Table 3 Variation in cluster sizes (number of eligible
participants per general practice) in two cluster
randomized trials in CPRD
Trial Estimate
Antibiotic trial
Participants Registered adults aged 18 to 59 years
Cluster size (median, IQR) 5,246 (3,608 to 7,219)
Minimum cluster size 811
Maximum cluster size 16,984
Mean (SD) cluster size 5,588 (2,938)
CV of cluster sizes 0.53
Stroke trial
Participants Patients with prevalent stroke
Cluster size (median, IQR) 102 (60 to 148)
Minimum cluster size 19
Maximum cluster size 343
Mean (SD) cluster size 110 (62)
CV of cluster sizes 0.56
CV, Coefficient of variation; IQR, Interquartile range; SD, Standard deviation.
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to non-responding practices about two months after the
initial invitation letter. In each trial, the recruitment target
of 100 practices was exceeded within six months of the
initial invitation letter.
Allocation of individual units to trial arms is a key de-
sign feature that protects against bias. In these two trials
anonymized identifiers, with linked data for region and
list size as stratifiers, were passed to King’s College
London for allocation by minimisation [18]. Anonymized
practice identifiers were then returned to CPRD with the
trial arm allocation attached. This information was then
used to enable intervention activation at practices in the
intervention trial arm. This procedure was considered to
ensure adequate concealment throughout the allocation
process.
Power and sample size
Estimating the size of a study is important in most trials.
For trials in CPRD, such calculations may be readily in-
formed by previously collected data. Sample size calcu-
lations for each trial, which drew on previous CPRD
data analyses by the research team, have been reported
previously [8,9]. However, analysis of trial data pro-
vided information concerning variability in cluster size,
the extent of variation between practices, and the correla-
tions between measures before and after intervention that
might be used to provide improved sample size calcula-
tions. Initial calculations did not include data for variabil-
ity in cluster sizes in terms of numbers of eligible
participants per practice [19]. Table 3 presents empirical
data for the distribution of cluster sizes in data from the
two trials.
As expected the mean cluster size differed considerably
between the two trials with 110 prevalent stroke patients
per practice in the stroke trial, but 5,588 registeredpatients aged 18 to 59 years per practice in the antibiotic
trial. The coefficient of variation for cluster sizes was re-
markably similar between the two trials, being 0.56 in the
stroke trial and 0.53 in the antibiotic trial. These estimates
are close to the median value for the coefficient of vari-
ation of practice list size (0.56, interquartile range 0.49 to
0.64) for all primary care organizations in England [20].
Eldridge et al. [20] showed that the design effect for a
study will be greater when cluster sizes are variable rather
than when they are uniform, with the usual design effect:
DE ¼ 1þ m−1½ ρ
being replaced by DE = 1 + [(cv2 + 1). m − 1]ρ (Equation 2)
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size, ρ is the intraclass correlation coefficient of the out-
come of interest, and cv is the coefficient of variation of
the cluster sizes. The latter formula indicates that the es-
timated design effect is likely to be substantially higher
when variation in cluster size is considered. In EHRs
research mean cluster sizes may often be large, as ob-
served in these two trials, potentially giving rise to sub-
stantial design effects.
The analysis of trial data also allowed us to estimate
the extent of variation in trial outcomes between practices.
Intraclass correlation coefficients (ICC) for outcomes of
blood pressure and total serum cholesterol from the
stroke trial are shown in Table 4. These values are similar
to estimates that we reported for pretrial analyses for the
period 2003 to 2006 [21]. Adams et al. [22] reported data
from 31 cluster-based studies in primary care, their 1,039
ICC estimates gave a median ICC of 0.01 (interquartile
range 0 to 0.032). In the present data, ICC values differed
slightly between intervention and control trial arms. This
apparent difference, which was evident both before and
after intervention, is unexplained and might result from
random error. This serves to draw attention to the
variability of ICC estimates that may be obtained from
a single data source. Equivalent data for the antibiotic
trial are shown in Table 5. Here coefficients of vari-
ation for practice-specific rates, rather than intraclass
correlation coefficients, are presented following the ap-
proach developed by Hayes and Bennett [23]. These
also indicate considerable variation between practices,
as we have described previously from a clinical per-
spective [24,25].
Tables 4 and 5 also present data for the correlation of
outcomes between the 12 months before interventionTable 4 Intraclass correlation coefficient (95% confidence inte
measures for the stroke trial
Intraclass correlation coefficient (ICC) (95%
Before Intervention Af
Systolic blood pressure (mmHg)
All trial participants 0.026 (0.016 to 0.037) 0.02
Control trial arm 0.043 (0.021 to 0.066) 0.03
Intervention trial arm 0.010 (0.002 to 0.018) 0.00
Diastolic blood pressure (mmHg)
All trial participants 0.023 (0.014 to 0.033) 0.01
Control trial arm 0.029 (0.013 to 0.046) 0.02
Intervention trial arm 0.018 (0.007 to 0.029) 0.01
Total serum cholesterol (mmol/L)
All trial participants 0.010 (0.004 to 0.016) 0.01
Control trial arm 0.015 (0.004 to 0.026) 0.01
Intervention trial arm 0.005 (0.000 to 0.012) 0.01and the 12 months after the start of intervention. In the
stroke trial, outcomes of blood pressure and total chol-
esterol were found to be highly correlated in individual
patient data, with correlation coefficients in excess of 0.4
for systolic and diastolic blood pressure and 0.7 for total
cholesterol. In the antibiotic trial, correlations from before
and after intervention were generally greater than 0.8 for
rates on consultation for respiratory tract infection, rates
of antibiotic prescribing, and the proportion of consulta-
tions with antibiotics prescribed. These correlations (r)
show that, although there is substantial variation between
practices and individuals, there is a considerable stability
of values over time within practices or individuals. When
trial analyses are performed in an analysis of covariance
(ANCOVA) framework, these correlations may result in
considerably more precise estimates than anticipated from
sample size calculations that only considered differences
between trial arms at the end of intervention [26]. The de-
sign effect appropriate for a post-test only analysis can be
multiplied by 1-r2 to correct for a clustered ANCOVA de-
sign [26,27]. The stability of estimates over time implied
by these correlations suggests that it may be worthwhile
to construct elements of trial analysis in the primary care
database in advance of the trial in order to obtain relevant
design parameters to inform sample size calculations.
However, in EHR research the marginal cost of increasing
the numbers of clusters in a study might be small, depend-
ing on the costs of intervention.
Intervention implementation
The purpose of intervention development and implementa-
tion was to deliver educational and decision support tools
to general practitioners (GPs) at the point-of-care during
routine consultations [12]. The intervention includedrval) and correlation between pre- and post-intervention
confidence interval) Correlation between outcome
measures before and after interventionter Intervention
2 (0.012 to 0.031) 0.43
7 (0.018 to 0.057) 0.46
8 (0.0005 to 0.015) 0.40
6 (0.009 to 0.024) 0.42
0 (0.008 to 0.033) 0.44
3 (0.004 to 0.022) 0.40
5 (0.007 to 0.022) 0.77
9 (0.007 to 0.031) 0.76
1 (0.003 to 0.020) 0.78
Table 5 Design parameters from the antibiotic trial
Coefficients of variation for general practice specific rates or proportions Correlation between
rates before and after interventionBefore intervention After intervention
RTI consultation rate
All trial practices 0.27 0.26 0.83
Control trial arm 0.22 0.24 0.75
Intervention trial arm 0.31 0.28 0.89
Antibiotic prescribing rate
All trial practices 0.35 0.36 0.82
Control trial arm 0.31 0.36 0.79
Intervention trial arm 0.38 0.35 0.88
Proportion of consultations with antibiotic prescribed
All trial practices 0.20 0.20 0.91
Control trial arm 0.20 0.20 0.91
Intervention trial arm 0.20 0.20 0.91
Figures are coefficients of variation of practice-specific rates or proportions and correlation coefficients between the same measures before and after intervention.
RTI, respiratory tract infection.
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links to guidelines and research evidence to support clin-
ical decision-making, as well as printable patient informa-
tion. Identifying a method through which the intervention
could be delivered was an important element of this pro-
ject. CPRD general practices utilise a software system
known as VISION. Initially, we considered utilising a be-
spoke program, which was to be developed in-house, to
deliver the intervention. This approach was used to facili-
tate patient recruitment in the CPRD clinical trials RET-
ROPRO and eLung which recruited from a much smaller
number of CPRD practices [28]. However, this approach
proved time-consuming and difficult. Instead, the inter-
vention was delivered through a system known as DXS
Point-of-Care [29] DXS UK Ltd, Farnham, UK, which is
already integrated into VISION. The DXS Point of Care
system delivered the intervention as a set of webpages
with multiple external links. When practices were allo-
cated to the intervention trial arm the intervention was
activated by DXS Point-of-Care. An increasing number of
CPRD practices use a version of VISION software that is
hosted on an external shared server. Implementation of
the intervention for these server-hosted practices proved
more technically challenging and time consuming, but
was achieved. An attractive feature of the DXS method
was the collection of data on utilisation of the interven-
tion. This enabled us to monitor GPs adherence to the
intervention and relate study outcomes to uptake and util-
isation of the intervention.
The intervention was activated through information
recorded into patients’ EHRs during consultations. In
the initial stages of the project it was only possible to
utilize Read medical codes, recorded during the index
consultation, to activate the intervention. In the antibiotictrial, which was completed first, the intervention was acti-
vated when a Read medical code for acute respiratory tract
infection was entered during a participant’s consultation.
Subsequently, access to a wider range of information from
the patient’s EHR was facilitated. For the stroke trial, the
intervention was activated during any consultation by a
patient who was included in the practice stroke register.
In the UK, general practices maintain registers of a
number of chronic diseases as a part of their contractual
obligations [30]. As part of this process the practice
maintains a register of all patients registered with stroke
or transient ischaemic attack. These were identified as
participants who were eligible for the intervention.
However, only patients with previous stroke were eli-
gible to be included in the trial analysis. Patients with
transient ischaemic attack were not included because
this diagnosis may have poor specificity in routine clin-
ical practice.
It is important to consider the behaviour of end-users
in the design and implementation of the intervention. In
these trials, communication of the intervention required
that end-users should click on a link in order to read the
intervention materials. This requires users to actively
seek new information to inform clinical practice even in
conditions that may be regarded as routine. Although
we had the capability to deliver active alerting through
the use of ‘pop-ups’, this approach was not used because
of qualitative evidence that active alerts are annoying
and off-putting to users. The intervention only became
active when information was entered into the clinical
record and for those general practitioners who only
enter clinical data after the end of the consultation the
opportunity to influence practice in that consultation
might be lost. However, the educational tools might have
Table 6 Illustrating the effect on sample size and participant characteristics at baseline of varying participant selection
criteria in the stroke trial. CPRD, Clinical Practice Research Datalink.
Number Age Gender Systolic blood pressure Total cholesterol
Mean (SD) Female (%) Mean (SD) Mean (SD)
Participants with prevalent stroke
All Non-trial CPRD practices 47,887 72.2 (14.0) 23,179 (48) 134.4 (15.3) 4.4 (1.0)
Trial practices 11,391 72.5 (14.0) 5,490 (48) 134.5 (15.6) 4.4 (1.0)
Participants with incident stroke since start of CPRD record
All Non-trial CPRD practices 27,971 72.5 (13.4) 13,369 (48) 134.8 (15.1) 4.4 (1.0)
Trial practices 6,296 72.5 (13.4) 2,950 (47) 135.0 (15.4) 4.4 (1.0)
Participants with incident stroke within two years of intervention start date
All Non-trial CPRD practices 7,530 71.4 (14.0) 3,629 (48) 136.6 (15.6) 4.5 (1.10)
Trial practices 1,706 72.0 (14.1) 797 (47) 136.3 (16.5) 4.5 (1.10)
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once.
Our experience shows that it is feasible to introduce
intervention materials into the software systems of
CPRD general practices that are participating in a trial.
Furthermore, it was possible to monitor the utilisation
of the intervention and conduct a qualitative process
evaluation to explore end-users’ experience of utilising
the intervention materials. However, future trials in CPRD
will need to develop a more diverse range of effective
interventions so as to broaden the scope of future
intervention studies.
Analysis issues
Trials in CPRD benefit from the assessment of outcomes
for large numbers of participants using data that are
routinely collected in EHRs. The strengths and limita-
tions of such data have been extensively considered else-
where. The two trials adopted differing approaches to
analysis with the stroke trial using an analysis of individual
participant level data [31] and the antibiotic trial utilising
a cluster level analysis of practice-specific rates and pro-
portions weighted to allow for varying cluster sizes [20].
These represent standard methods of analysis. However,
in a primary care database such as CPRD there is unusualTable 7 General practice eligibility for analysis in the two tria
UTS start to
intervention start
(median IQR, Years)
Number of practices
with UTS start >
intervention start
Interve
last col
(media
Antibiotic trial
Intervention practices 11.9 (8.6 to 14.9) 2 1.6 (1.4
Control practices 12.1 (9.3 to 17.5) 1 1.5 (1.4
Stroke trial
Intervention practices 12.4 (9.9 to 19.9) 0 1.3 (1.2
Control practices 13.7 (11.2 to 21.5) 0 1.4 (1.3
IQR, interquartile range; UTS, up-to-standard.flexibility in the selection of data for analysis, and this may
be of considerable importance. In order to inform future
research studies we first discuss the selection of stroke
cases and eligibility criteria for the stroke trial. We then
go on to consider issues of person time and the inclusion
of general practices in the analysis.Individual participants and eligibility criteria
In primary care EHRs, cases are generally selected on the
basis of Read medical codes. The Read code classification
is partly hierarchical, drawing on disease categories that
map to the International Classification of Diseases. How-
ever, there are also codes for symptoms, clinical signs,
medical tests, and interventions among others. This re-
sults in a diverse range of codes being available to code
a condition such as stroke. Typically, small numbers of
codes are frequently used, while a broader range of
codes may be used at intermediate or low frequency.
We have previously reported on the use of medical
diagnostic codes for stroke in CPRD [32], presenting a
range of options for case definition of stroke. For the
present study we used a stringent definition, including
only codes that were considered to provide firm evidence
of an acute stroke.ls
ntion start to
lection date
n IQR, Years)
Number of practices
with last collection
before intervention start
Number of practices with last
collection before intervention
start plus one year
to 1.7) 1 1
to 1.7) 0 4
to 1.4) 0 2
to 1.5) 2 3
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possibilities for including individual participants, as out-
lined in Table 6. The most inclusive option for the stroke
trial was to include all participants with acute stroke
ever recorded before the intervention start date. There
were 11,391 participants at trial practices that met this
criterion for prevalent stroke who survived to the start
of intervention. A second option was to include partici-
pants with acute stroke recorded as an incident event
more than 12 months after the start of the current regis-
tration in CPRD. This criterion excluded participants
with prevalent stroke diagnoses from before the start of
the ‘up-to standard’ CPRD record for whom the initial
diagnoses might be less secure. There were 6,296 partici-
pants with incident strokes at trial practices (Table 6). A
third option, which was initially considered in the trial
protocol [9], was to include only participants with acute
stroke within two years of the trial intervention start
date. The rationale for this criterion was that GPs might
be more amenable to modifying the management of par-
ticipants with recent strokes. There were 1,706 partici-
pants at trial practices with incident strokes in the two
years before the intervention start date. Table 6 presents
selected baseline characteristics according to these three
eligibility criteria for trial practices and for participants
at non-trial CPRD practices. In this trial, participant
characteristics were similar after selection according to
either criterion, although participants with more recent
strokes tended to have slightly higher blood pressure
and total cholesterol values. Participant characteristics
were also similar for trial and non-trial practices. The
major impact of varying the inclusion criteria was on the
sample size available for analysis. It is possible that, in a
different trial, varying the inclusion criteria in this way
might have a substantial impact on participant character-
istics and estimated intervention effects. Ideally, pretrial
analyses in CPRD would be sufficient to develop clearly
defined eligibility criteria. Additionally, it is desirable to
perform a sensitivity analysis to explore the effect of vary-
ing trial inclusion criteria.
Person time-at-risk and practices with no participants
Most CPRD studies employ longitudinal data analysis
based on person time-at-risk. For CPRD practices, time-
at-risk begins at the practice’s UTS start date and ends
at the last data collection date. The latter reflects the
most recent data collection from the practice but this
may also indicate when the practice left the CPRD. For
individual participants, time-at-risk starts at the date of
their current registration (if this is after the practice’s
UTS start date) and ends at the end of the registration
or death (if these are before the practice’s last data
collection date). Table 7 shows the time from UTS start
to intervention start for trial practices. The medianduration of participation in CPRD before the start of the
trial was approximately 12 years for both the stroke trial
and the antibiotic trial. In the stroke trial, the UTS date
was before the intervention start date for all practices.
However, in the antibiotic trial the UTS start date was
found to be after the intervention start date for three prac-
tices, two in the intervention trial arm and one in the con-
trol trial arm. These practices were omitted from the
analysis because participant data were only eligible
from the UTS start date and pre-intervention as well
as post-intervention observations were required for
analysis. Table 7 also shows the median interval from
intervention start to last data collection date; this was
more than one year as intended. However, there were
two control practices in the stroke trial and one inter-
vention practice in the antibiotic trial with a last col-
lection date that was before the intervention start date.
These practices were omitted from the analysis. There
were a further number of practices for which the last
data collection date fell before the end of 12 months
after the intervention. These practices’ data were ana-
lysed on the basis of person time-at-risk. These obser-
vations point to the importance of considering practices
eligibility for analysis over time in relation to the imple-
mentation of the intervention.
Conclusions
There is great interest in conducting clinical trials using
EHRs but few trials have yet been completed. Our ex-
perience of completing two cluster randomized trials has
identified several issues of methodological importance.
The governance of a trial using EHRs may represent a
time-consuming and challenging process, and this needs
to be taken into account at the planning stage. The de-
sign and analytical approaches to be employed in a
trial using EHRs should carefully consider case defini-
tions, eligibility criteria for practices, and individual
participants. The definition, recording, and variability
of outcome measures also require consideration. These
issues may often be addressed through pretrial analysis
of EHR data. Future studies should aim to increase the
scope and complexity of interventions that can be de-
livered in EHR-based trials with attention to behav-
ioural considerations that may influence uptake and
effectiveness.
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